Christensenella minuta Microbiome CRO Services

Q: Can you integrate host models into C. minuta functional studies?

Yes. Depending on project scope, we combine C. minuta with in vitro epithelial, immune, or organoid models and, where appropriate, coordinate preclinical in vivo experiments through partners. This enables coherent assessment of metabolic, inflammatory, and neuromodulatory endpoints.

Creative Biolabs supports microbiome, live biotherapeutic, and NGP developers by delivering end-to-end Christensenella minuta–focused CRO solutions. From strain isolation and characterization to functional, interaction, and safety profiling, we help teams de-risk C. minuta programs and generate decision-ready data across discovery and preclinical research.

Preferred Partner for C. minuta Microbiome Programs

Leading microbiome innovators rely on Creative Biolabs for robust, strain-level C. minuta data packages that withstand scientific and regulatory scrutiny.

Why Invest in C. minuta Microbiome CRO Services

C. minuta has emerged as a keystone gut commensal consistently linked to a lean body phenotype, favorable metabolic profiles, and heritable microbiome signatures. Human cohort studies and preclinical models associate higher C. minuta abundance with lower BMI, improved metabolic status, and distinct microbial networks.

Beyond metabolic traits, multiple strains of C. minuta demonstrate anti-inflammatory, barrier-protective, hepatoprotective, and neuromodulatory effects in vitro and in vivo, including benefits in colitis, stress-related behaviors, and drug-induced liver injury. This diversity of host interactions makes C. minuta a priority candidate in next-generation probiotic pipelines and microbiome-based mechanism studies. Creative Biolabs integrates this evidence into tailored study designs so your C. minuta projects move from concept to robust data efficiently.

C. minuta microbiome services (Creative Biolabs Original)

End-to-End C. minuta Microbiome CRO Services

Microbial Isolation and Screening Services

Creative Biolabs isolates C. minuta from complex fecal or intestinal samples using dedicated ultra-low-oxygen workflows and selective media. We then screen C. minuta isolates for growth performance, oxygen sensitivity, SCFA production, and genetic stability, enabling you to prioritize the most promising strains for downstream discovery and formulation studies.

Microbial Identification Services

Our microbial identification services combine 16S rRNA sequencing, whole-genome sequencing, and strain-specific markers to confirm C. minuta identity at species and sub-strain levels. We distinguish C. minuta from closely related Christensenellaceae members and characterize key genomic features, ensuring that your C. minuta collections remain traceable, well-annotated, and suitable for regulatory-ready documentation.

Microbial Fermentation Services

Creative Biolabs has established dedicated ultra-low-oxygen fermentation systems optimized for C. minuta, including controlled redox potential, customized media, and gentle downstream handling. We support lab-scale C. minuta biomass generation, conditioned media and metabolite harvest, and process optimization studies, providing high-viability material for in vitro, ex vivo, and preclinical research models.

Microbial Stabilization Services

C. minuta is typically considered extremely oxygen-sensitive, yet strains show heterogeneous oxygen tolerance profiles. Creative Biolabs designs stabilization strategies tailored to C. minuta, including cryoprotectant screening, lyophilization or frozen formats, anaerobic or oxygen-scavenging packaging, and accelerated stability studies. These services support real-world handling scenarios and long-distance shipment for multi-site research programs.

Functional and MoA Screening

To reveal the functional landscape of C. minuta, we implement multi-layered functional and mechanism-of-action screening. Platforms include metabolic readouts (SCFA and bile acid profiles), host gene expression panels, inflammatory mediator assays, energy expenditure–related endpoints, and pathway-focused omics. This helps clarify how C. minuta influences metabolism, immune tone, and neuromodulatory axes in preclinical systems.

Host–Microbe Interaction Tests

Creative Biolabs models C. minuta–host interactions using advanced in vitro and ex vivo systems, including intestinal epithelial cocultures, barrier integrity assays, mucus models, and immune cell co-culture platforms. These assays quantify how C. minuta affects tight-junction function, inflammatory signaling, stress pathways, and metabolic regulators, supporting rational target and indication selection.

Carbohydrate Fermentative Profiles

We characterize C. minuta carbohydrate utilization and fermentation profiles across defined carbon sources. Using SCFA analysis platforms (GC, HPLC, or NMR), Creative Biolabs quantifies acetate, butyrate, and other metabolites to link C. minuta substrate preferences with energy harvest, gut barrier modulation, and signaling via SCFA receptors in host tissues.

Biological Safety Test Services

For C. minuta–based live biotherapeutic research, Creative Biolabs builds GRAS/QPS-aligned safety dossiers. We assess C. minuta for hemolytic activity, cytotoxicity, acquired antibiotic resistance, virulence factors, mobile genetic elements, and genome-encoded safety markers, generating structured reports that support internal governance, partner due diligence, and early regulatory dialogue.

Workflow for C. minuta Microbiome CRO Projects

Study scoping and design

Define C. minuta strain, model systems, endpoints, and regulatory expectations.

Sample and strain onboarding

Receive samples or strains, confirm identity, and establish master working stocks.

Assay and model setup

Configure anaerobic culture, functional assays, and host-interaction platforms to project needs.

Execution and QC

Run C. minuta experiments with integrated viability, purity, and method controls.

Data analysis and interpretation

Integrate microbiology, omics, and host-response data into coherent study narratives.

Reporting and next-step planning

Deliver structured reports and propose follow-on studies for pipeline progression.

Advantages of Partnering with Creative Biolabs for C. minuta

Keystone-species focus

Deep experience with C. minuta and other next-generation probiotics.

Anaerobic excellence

Mature ultra-low-oxygen workflows for fragile gut commensals.

Integrated analytics

Microbiology, SCFA, bile acids, and host-omics on one platform.

Flexible engagement models

From feasibility screens to multi-year C. minuta programs.

Regulatory-oriented documentation

Data packages structured for GRAS/QPS and LBPs.

Collaborative project management

Scientific guidance from proposal through final reporting.

Research Applications of C. minuta in Microbiome Science

Obesity and Body-Weight Regulation Models

Preclinical studies show that selected C. minuta strains attenuate diet-induced weight gain, reduce adiposity, and modulate hepatic lipogenesis while reshaping the gut microbiota and Firmicutes/Bacteroidetes ratio. These data underpin C. minuta use in metabolic health–oriented research portfolios.

Glucose and Lipid Metabolism in Type 2 Diabetes Research

C. minuta has been implicated in improved glycemic control, insulin signaling, and lipid handling in metabolic models. Creative Biolabs supports studies where C. minuta is evaluated alongside diet or small-molecule modulators to dissect microbiome contributions to glucose homeostasis and dyslipidemia.

Intestinal Inflammation and Barrier Integrity

Multiple C. minuta strains demonstrate robust anti-inflammatory and barrier-protective effects in colitis models, strengthening tight junctions and reducing colonic inflammation. Our platforms allow detailed assessment of C. minuta in IBD-relevant in vitro and in vivo models, focusing on cytokines, barrier function, and epithelial repair dynamics.

Stress, Mood, and Gut–Brain Axis Investigations

Recent work shows C. minuta can mitigate stress-induced depressive and anxiogenic behaviors while modulating the HPA axis, dopaminergic pathways, and cardiometabolic stress markers. Creative Biolabs supports gut–brain axis projects that integrate behavioral endpoints with microbiome, metabolite, and inflammatory signatures.

Liver Injury and Cardiometabolic Damage Models

C. minuta has been reported to alleviate acetaminophen-induced hepatotoxicity and reduce liver fibrosis-related markers, partly through phenylalanine and bile acid metabolism modulation. In addition, cardiometabolic readouts improve in stress-linked models, supporting its inclusion in gut–liver and cardiovascular research designs.

Probiotic Development, Biomarkers, and Animal Husbandry

As a highlighted next-generation probiotic candidate, C. minuta is central to LBP discovery, formulation screening, and microbiome-based health biomarkers. Its abundance patterns across populations and host species also inform animal nutrition strategies, where modulating C. minuta levels may support tailored weight-gain and metabolic outcomes in livestock systems.

Sample submission form (Creative Biolabs Original)

You may submit your request form, and our team will prepare a customized C. minuta study plan aligned with your specific research objectives.

Submit Sample Form

C. minuta Related Products

Creative Biolabs provides C. minuta strains for your research.

Product Name	Catalog No.	Target	Product Overview	Size	Price
Christensenella minuta	LBST-046FG	Christensenella	Christensenella minuta is an anaerobe, mesophilic, Gram-negative bacterium that was isolated from faeces from a healthy Japanese male.	—	Inquiry

FAQs

We routinely process human and animal fecal samples, intestinal content, and biobank materials. Our anaerobic pipelines are optimized to recover extremely oxygen-sensitive C. minuta while preserving community-level context for downstream comparative studies.

Viability is safeguarded through strict anaerobic handling, customized media, and controlled cryostorage or lyophilization. Purity is confirmed using culture-based methods, 16S profiling, and WGS when needed, ensuring that each C. minuta strain remains genetically and phenotypically stable.

Yes. Depending on project scope, we combine C. minuta with in vitro epithelial, immune, or organoid models and, where appropriate, coordinate preclinical in vivo experiments through partners. This enables coherent assessment of metabolic, inflammatory, and neuromodulatory endpoints.

Other Resources

C. minuta in Obesity and Metabolic Health - Resource

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic Strain Products for NGP Research - Brochure

Custom Small-scale Probiotic Production - Brochure

Live Biotherapeutics - Creative Biolabs - Video

References

Mazier, Wilfrid, et al. "A New Strain of Christensenella minuta as a Potential Biotherapy for Obesity and Associated Metabolic Diseases." Cells 10.4 (2021): 823. https://doi.org/10.3390/cells10040823
Kropp, Camille, et al. "The Keystone Commensal Bacterium Christensenella minuta DSM 22607 Displays Anti-Inflammatory Properties Both in Vitro and in Vivo." Scientific Reports 11 (2021): 11494. https://doi.org/10.1038/s41598-021-90885-1
Agusti, A., et al. "Christensenella minuta Mitigates Behavioral and Cardiometabolic Hallmarks of Social Defeat Stress." Biomedicine and Pharmacotherapy 180 (2024): 117377. https://doi.org/10.1016/j.biopha.2024.117377
Yao, Ting, et al. "Christensenella minuta Alleviates Acetaminophen-Induced Hepatotoxicity by Regulating Phenylalanine Metabolism." Nutrients 16.14 (2024): 2314. https://doi.org/10.3390/nu16142314
Ignatyeva, Olga, et al. "Christensenella minuta, a New Candidate Next-Generation Probiotic: Current Evidence and Future Trajectories." Frontiers in Microbiology 14 (2023): 1241259. https://doi.org/10.3389/fmicb.2023.1241259

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

ISO 9001 Certified - Creative Biolabs Quality Management System.

Tel:
Fax:
Email:
Global

Inquiry Basket